Halozyme Therapeutics, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company that develops and commercializes proprietary enzyme-based drug delivery technologies and oncology therapies. The company's core ENHANZE platform, powered by the patented recombinant human hyaluronidase enzyme (rHuPH20), facilitates subcutaneous delivery of injectable biologics including monoclonal antibodies, other therapeutic molecules, small molecules, and fluids; it supports partnered products such as DARZALEX FASPRO (subcutaneous), Phesgo, VYVGART Hytrulo, Tecentriq Subcutaneous, and Ocrevus Subcutaneous across oncology, immunology, and neurology indications. Halozyme also commercializes XYosted, a testosterone replacement therapy via an auto-injector, and previously marketed Hylenex and Tlando prior to license terminations. Founded in 1998 and headquartered in San Diego, California, Halozyme operates primarily in the United States with global partnerships enabling international reach through collaborators in pharmaceutical and biotechnology sectors targeting diabetes, cancer, dermatology, autoimmune diseases, and rare disorders. In recent developments, Halozyme completed the acquisition of Elektrofi in late 2025 for up to $900 million, integrating the Hypercon microparticle technology to expand subcutaneous delivery options and strengthen partnerships with big pharma; the deal includes $750 million upfront plus milestones tied to product approvals, with royalties expected from 2030. The company expanded its argenx collaboration with an upfront payment and milestones, secured a new global agreement with Merus N.V. for ENHANZE in bispecific antibodies, and gained regulatory approvals for Roche's Tecentriq and Ocrevus subcutaneous formulations; partners nominated five new targets for clinical advancement in 2024, contributing to record 2024 revenue exceeding $1 billion. These initiatives underscore Halozyme's focus on organic pipeline growth, strategic alliances, and share repurchases up to $250 million.
Company News
Halozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
4 Value Stocks to Buy as Oil Surge Fuels Fed Rate Hike Fears
4 Best PEG Value Stocks to Buy Now for Strong Growth & Return
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,144,800.00 in Stock
VIRGINIA RETIREMENT SYSTEMS ET Al Takes $1.02 Million Position in Halozyme Therapeutics, Inc. $HALO
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,148,600.00 in Stock
Squarepoint Ops LLC Sells 25,257 Shares of Halozyme Therapeutics, Inc. $HALO
Record Revenue Growth Boosts Halozyme Shares
Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT?
Halozyme Therapeutics, Inc. (HALO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
4 High-Growth GARP Stocks With Discounted PEG Ratios for 2026
Halozyme to Participate at Upcoming Investor Conferences
Halozyme: The Market May Be Underpricing The Second Growth Wave
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Canada Pension Plan Investment Board Purchases Shares of 132,600 Halozyme Therapeutics, Inc. $HALO
Freestone Grove Partners LP Acquires New Stake in Halozyme Therapeutics, Inc. $HALO
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice
5 Value Stocks to Buy Right Now as Inflation Remains Sticky
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
5 Biotech Stocks Worth Adding to Your Portfolio Now